Physician

Atil Yilmaz Kargi, M.D.

According to 2025 Medicare claims, Atil Kargi, M.D. (NPI: 1902918949) practices endocrinology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (NPI: 1780669200; TIN: 561732213) and primary practice location at 27514-4617. Kargi is affiliated with the CHESS Genesis, LLC (ACO ID: D0237), participating under the REACH model.

Kargi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 41 traditional Medicare patients, billed 70 HCPCS/CPT codes, and received $6,916 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 200 prescription claims across 37 beneficiaries totaling $490,570 in drug costs, led by Somavert (Pegvisomant). 2023 DME data shows 19 claims. Open Payments data shows 66 records totaling $39,563. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $23,730 to $6,916. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $243,699 and ending at $490,570. For DME billing, reported payments moved from a lower plateau to a higher plateau, from $2,039 to $4,580.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	185	396	$23,730
2016	150	341	$15,801
2017	163	280	$17,617
2018	163	279	$17,658
2019	134	244	$15,823
2020	130	228	$17,340
2021	184	297	$26,749
2022	187	263	$23,151
2023	20	32	$3,389
2024	41	70	$6,916

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	115	1,134	$243,699
2016	102	943	$244,112
2017	111	930	$516,677
2018	130	1,101	$562,091
2019	148	1,137	$623,501
2020	148	1,222	$744,217
2021	162	1,299	$959,342
2022	165	1,208	$1,149,818
2023	85	294	$162,261
2024	37	200	$490,570

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	47	109	$1,933
2016	35	113	$2,280
2017	30	84	$991
2018	26	71	$1,024
2019	14	67	$949
2020	N/R	36	$437
2021	N/R	47	$4,487
2022	N/R	36	$3,825
2023	N/R	19	$3,621
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	17	17	$121
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	13	26	$109
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	11	17	$71

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Somavert	Pegvisomant	13	390	$180,105
Cabergoline	Cabergoline	22	1,518	$2,328
Testosterone	Testosterone	15	450	$1,253
Hydrocortisone	Hydrocortisone	39	1,405	$1,083
Testosterone Cypionate	Testosterone Cypionate	23	672	$453

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	26	$38,957	RECORDATI_RARE_DISEASES_INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	40	$606	Novo Nordisk AS
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Atil Yilmaz Kargi, M.D.?

Tedicare shows public-source Medicare data for Atil Yilmaz Kargi, M.D. (NPI 1902918949), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Atil Yilmaz Kargi, M.D. have ACO affiliation data?

Atil Yilmaz Kargi, M.D. is shown with ACO affiliation data for CHESS Genesis, LLC (REACH, ACO ID D0237).

What billing organization is linked to Atil Yilmaz Kargi, M.D.?

Atil Yilmaz Kargi, M.D. is linked to UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (billing NPI 1780669200) in the available physician profile data.

Does Atil Yilmaz Kargi, M.D. have Open Payments data?

Atil Yilmaz Kargi, M.D. has 66 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.